| progressive supranuclear palsy |
phenotype |
2 |
— |
|
| pro-inflammatory cytokines |
phenotype |
5 |
6 |
|
| proinflammatory response |
phenotype |
2 |
1 |
|
| proliferative cells |
phenotype |
2 |
2 |
|
| proline |
drug |
2 |
1 |
|
| promiscuity |
phenotype |
2 |
2 |
|
| promoter |
drug |
4 |
1 |
promoter region |
| propensity to smoke |
phenotype |
2 |
1 |
|
| propidium iodide |
drug |
4 |
3 |
PI |
| propofol |
drug |
2 |
2 |
|
| PROS1 |
gene |
2 |
2 |
|
| prosocial behavior |
phenotype |
5 |
3 |
prosocial, prosocial behavior |
| Prospective Study |
cohort |
7 |
4 |
prospective cohorts |
| prostaglandin E2 |
drug |
3 |
2 |
PGE2 |
| Prostaglandins |
drug |
2 |
1 |
|
| prostate cancer |
phenotype |
23 |
6 |
PCa, prostate cancer, prostate carcinoma |
| protease |
drug |
2 |
— |
|
| protease inhibitor cocktail |
drug |
4 |
1 |
|
| protease inhibitors |
drug |
3 |
1 |
|
| protein |
drug |
21 |
3 |
protein |
